Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Radioligand Therapy (RLT) in Neuroendocrine Neoplasms
share announcement

Radioligand Therapy (RLT) in Neuroendocrine Neoplasms

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 356

Special Issue Editor

Prof. Dr. Grzegorz Kamiński

E-Mail Website
Guest Editor
Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine—National Research Institute, Szaserów 128, 04-141 Warsaw, Poland
Interests: neuroendocrine neoplasms; radioligand therapy; thyroid cancer

Special Issue Information

Dear Colleagues,

The treatment methods for neuroendocrine neoplasms (NENs) have been rapidly advancing in recent years. New treatment models now include the use of radioligand therapy (RLT) as an earlier line of treatment. The use of radiopharmaceuticals introduces new possibilities for patients, extending their progression-free survival and overall survival compared to other therapies.

In light of this, we would like to extend an invitation to all researchers working in the field of neuroendocrine neoplasms and radioligand therapies to contribute to a Special Issue of Cancers entitled "Radioligand Therapy (RLT) in Neuroendocrine Neoplasms". We hope that you will share your experiences and study results with us. In addition to original articles, comprehensive reviews are also welcomed.

We anticipate that the deadline of 31 October 2024, will be acceptable for all contributors and provide sufficient time for the preparation of high-value publications.

Prof. Dr. Grzegorz Kamiński
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuroendocrine neoplasms (NENs)
  • neuroendocrine tumors (NETs)
  • radioligand therapy (RLT)
  • peptide receptor radionuclide therapy (PRRT)

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 834 KiB  
Article
Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach
by Paweł Komarnicki, Paweł Gut, Maja Cieślewicz, Jan Musiałkiewicz, Adam Maciejewski, Michalina Czupińska, George Mastorakos and Marek Ruchała
Cancers 2024, 16(11), 2060; https://doi.org/10.3390/cancers16112060 - 29 May 2024
Viewed by 105
Abstract
Despite recent advances, neuroendocrine tumors (NETs) remain a challenging topic, due to their diversity and the lack of suitable biomarkers. Multianalyte assays and the shift to an omics-based approach improve on the conventional single-analyte strategy, albeit with their own drawbacks. We explored the [...] Read more.
Despite recent advances, neuroendocrine tumors (NETs) remain a challenging topic, due to their diversity and the lack of suitable biomarkers. Multianalyte assays and the shift to an omics-based approach improve on the conventional single-analyte strategy, albeit with their own drawbacks. We explored the potential of serum β-hCG as a biomarker for NETs and discussed its role in disease monitoring. We recruited 40 patients with non-functioning pancreatic NETs, all with liver metastases. Serum β-hCG concentrations were measured at 3-month intervals over 48 months. We performed a comparative and a repeated measures analysis of β-hCG depending on WHO grade (G1, G2), liver tumor burden (LTB; below 10%, 10–25%), and RECIST 1.1. (stable disease, progressive disease). Patients with progressive disease (p < 0.001), 10–25% LTB (p < 0.001) and WHO Grade 2 (p < 0.001) displayed higher β-hCG concentrations. Throughout the study, β-hCG concentrations consistently increased across the entire cohort. Delta β-hCG during the study period was greater in patients with 10–25% LTB (p < 0.001), progressive disease (p < 0.001), and G2 (p = 0.003). Serum β-hCG correlates with established indicators of malignancy and disease progression in metastatic NETs, supporting further studies as a monitoring and prognostic biomarker. Despite promising results from novel biomarkers, there is still a place for single-analyte assays in NETs. Full article
(This article belongs to the Special Issue Radioligand Therapy (RLT) in Neuroendocrine Neoplasms)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop